Vendor Intelligence Report: Zhejiang Jiuzhou Chem Co

Published 2 Jul 2026. 22-page investigative report on who is behind Zhejiang Jiuzhou Chem Co: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 4 Finnrick lab tests, Zhejiang Jiuzhou Chem Co records 4 pass / 0 fail, for a 100% overall pass rate. The signal is favorable but narrow: every Finnrick result in scope is Tirzepatide. That makes the vendor a more reasonable candidate for Tirzepatide than its opaque corporate file alone would suggest, while leaving non-Tirzepatide products unsupported by product-specific Finnrick evidence. The full report shows how this one-product rating behaves under stricter grading.

The diligence file is less tidy than the lab score. The listed official domain currently returns a CDN/404 error, pushing verification onto marketplace profiles and archived captures. A UK Companies House trail shows a short-lived, dormant namesake company that later dissolved, which conflicts with marketplace longevity language and limits any practical recourse a gray-market buyer could expect from the UK entity.

The strongest operating lead points to Zhejiang Hangyu API: the report documents a shared phone channel and reused marketing copy across separate web identities, while stopping short of claiming formal ownership. It also separates Jiuzhou Chem from the similarly named listed Zhejiang Jiuzhou Pharmaceutical, where the name/address proximity and old FDA context create authentication risk but not proof of misconduct by Jiuzhou Chem.

For buyers, the useful read is product-specific. Tirzepatide has a positive Finnrick signal, the broader catalog lacks transparent batch-specific third-party COAs from named labs, and the promotion scan found no visible referral-code machine in the channels searched.

Inside the full report:

  • Appendix A laboratory table and methodology-divergence chart for Tirzepatide
  • Companies House filing trail for the dissolved UK namesake and officers
  • Hangyu API overlap analysis using shared phone and copied marketing language
  • Marketplace-listing review across LookChem, ChemicalBook, and ChemBlink
  • Jiuzhou Pharmaceutical name/address comparison and FDA-warning context
  • Promotion-footprint sweep across X, coupon-site, and Reddit-visible web searches

Risk assessment

  • Corporate-accountability risk — high: UK ZHEJIANG JIUZHOU CHEM CO., LTD was dormant and dissolved on 7 Apr 2026; the current operating counterparty is unclear.
  • Catalog COA and batch-traceability risk — high: Outside Finnrick-tested Tirzepatide, supplied listings show generic purity claims and no batch-specific third-party COAs from named labs.
  • Brand-confusion and authenticity-verification risk — medium: jiuzhou-chem.com currently returns a 404/CDN error, while Jiuzhou Chem overlaps with Hangyu API and resembles a separate listed Jiuzhou pharma company.
  • Non-Tirzepatide Finnrick coverage gap — medium: Finnrick data cover Tirzepatide only: 4 tests, 4 pass / 0 fail; non-Tirzepatide products have no Finnrick safety signal.